- Home
- ALNY vs EIX Comparison
ALNY vs EIX Comparison
Compare ALNY & EIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- EIX
- Stock Information
- Founded
- ALNY 2002
- EIX 1886
- Country
- ALNY United States
- EIX United States
- Employees
- ALNY N/A
- EIX N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- EIX Electric Utilities: Central
- Sector
- ALNY Health Care
- EIX Utilities
- Exchange
- ALNY Nasdaq
- EIX Nasdaq
- Market Cap
- ALNY 33.1B
- EIX 30.2B
- IPO Year
- ALNY 2004
- EIX N/A
- Fundamental
- Price
- ALNY $245.44
- EIX $79.50
- Analyst Decision
- ALNY Buy
- EIX Buy
- Analyst Count
- ALNY 23
- EIX 14
- Target Price
- ALNY $298.59
- EIX $86.11
- AVG Volume (30 Days)
- ALNY 671.5K
- EIX 2.2M
- Earning Date
- ALNY 02-13-2025
- EIX 10-29-2024
- Dividend Yield
- ALNY N/A
- EIX 4.16%
- EPS Growth
- ALNY N/A
- EIX 6.63
- EPS
- ALNY N/A
- EIX 3.42
- Revenue
- ALNY $2,094,795,000.00
- EIX $17,321,000,000.00
- Revenue This Year
- ALNY $25.14
- EIX $7.64
- Revenue Next Year
- ALNY $17.35
- EIX $4.34
- P/E Ratio
- ALNY N/A
- EIX $23.28
- Revenue Growth
- ALNY 21.54
- EIX 4.04
- 52 Week Low
- ALNY $141.98
- EIX $63.15
- 52 Week High
- ALNY $304.39
- EIX $88.77
- Technical
- Relative Strength Index (RSI)
- ALNY 43.56
- EIX 35.65
- Support Level
- ALNY $233.41
- EIX $77.42
- Resistance Level
- ALNY $249.58
- EIX $82.48
- Average True Range (ATR)
- ALNY 7.63
- EIX 1.51
- MACD
- ALNY -0.21
- EIX -0.62
- Stochastic Oscillator
- ALNY 48.68
- EIX 22.96
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About EIX Edison International
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.